D. Chang

发表

Taxol increases the amount and T cell activating ability of self-immune stimulatory multimolecular complexes found in ovarian cancer cells.

A. García-Sastre, S. Ferrone, Xinhui Wang, 2007, Cancer research.

Granulocyte-Macrophage Colony Stimulating Factor: An Adjuvant for Cancer Vaccines

M. Perales, R. Stan, D. Chang, 2004, Hematology.

Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin‐based chemotherapy for colorectal liver metastases

L. Ellis, S. Curley, E. Abdalla, 2007, Cancer.

Clinical significance of BRAF mutations in metastatic melanoma

D. Polsky, P. Chapman, I. Osman, 2004, Journal of Translational Medicine.

A Randomized Phase II Study of Immunization With Dendritic Cells Modified With Poxvectors Encoding CEA and MUC 1 Compared With the Same Poxvectors Plus GM-CSF for Resected Metastatic Colorectal Cancer

Anuradha, J. Marshall, D. Hsu, 2013 .

A Randomized Phase II Study of Immunization With Dendritic Cells Modified With Poxvectors Encoding CEA and MUC1 Compared With the Same Poxvectors Plus GM-CSF for Resected Metastatic Colorectal Cancer

J. Marshall, D. Hsu, T. Crocenzi, 2013, Annals of surgery.

Systemic Chemotherapy and Two-Stage Hepatectomy for Extensive Bilateral Colorectal Liver Metastases: Perioperative Safety and Survival

S. Curley, E. Abdalla, J. Vauthey, 2007, Journal of Gastrointestinal Surgery.

Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer.

H. Hurwitz, D. Niedzwiecki, G. Blobe, 2021, The oncologist.

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer

A. Dalgleish, D. Adamson, J. Stebbing, 2016, British Journal of Cancer.

Cancer Therapy: Preclinical DownregulationofHumanEndogenousRetrovirus Type K (HERV-K) Viral env RNA in Pancreatic Cancer Cells Decreases Cell Proliferation and Tumor Growth

Donghui Li, Yue Lu, Jianjun Shen, 2019 .

Phase II study of RAD001 (everolimus) and depot octreotide (sandostatin LAR) in advanced low grade neuroendocrine carcinoma (LGNET)

F. Meric-Bernstam, R. Wolff, A. Phan, 2007 .

HLA-A0201 positive pancreatic cell lines: new findings and discrepancies

P. Hwu, G. Lizée, J. Abbruzzese, 2007, Cancer Immunology, Immunotherapy.

Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).

N. Sharma, M. Fakih, J. Bendell, 2021 .

A phase II study of active immunotherapy with PANVAC or autologous, cultured dendritic cells infected with PANVAC after complete resection of hepatic metastases of colorectal carcinoma.

J. Marshall, M. Morse, D. Cole, 2006, Clinical colorectal cancer.

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer

A. Dalgleish, D. Adamson, J. Stebbing, 2016, British Journal of Cancer.

Effects of base excision repair gene polymorphisms on pancreatic cancer survival

Manal M. Hassan, Douglas B. Evans, R. Wolff, 2007, International journal of cancer.

Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokinetics

T. Olencki, R. Ganapathi, B. Osterwalder, 2001, Cancer Chemotherapy and Pharmacology.

Preliminary results from a phase II study of infusional 5-FU, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC).

S. Kopetz, R. Wolff, J. Abbruzzese, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy.

C. Liu, Chun Xing Li, P. Hwu, 2009, Vaccine.

ASIC — LIVER , PANCREAS , AND BILIARY RACT as Activity Levels Control the Development of Pancreatic Diseases

Huamin Wang, C. Logsdon, D. Longnecker, 2022 .

Phase II study of RAD001 (everolimus) and depot octreotide (Sandostatin LAR) in patients with advanced low grade neuroendocrine carcinoma (LGNET).

F. Meric-Bernstam, A. Phan, J. Mares, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mitogen stimulation activates different signaling pathways in early- and late-divided T cells as revealed by cDNA microarray analysis.

K. Wong, S. Matsueda, N. Tsuda, 2006, International journal of molecular medicine.

Acupuncture to Prevent Prolonged Postoperative Ileus: A Randomized Controlled Trial

J. Skibber, B. Feig, J. Palmer, 2008 .

Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall‐cell lung cancer, or pancreatic cancer

Ying Zhang, Razelle Kurzrock, Zhiqiang Meng, 2009, Cancer.

Prospective randomised evaluation of traditional Chinese medicine combined with chemotherapy: a randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomas

C. Garrett, L. Cohen, A. Spelman, 2012, British Journal of Cancer.

Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies

E. Petricoin, M. Goetz, H. Bear, 2020, Cancers.

Novel natural immunogenic peptides from Numb1 and Notch1 proteins for CD8+ cells in ovarian ascites.

J. Celestino, L. Jones, S. Matsueda, 2007, International journal of oncology.

Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity.

Suyun Huang, Jun Zhang, X. Le, 2010, Cancer research.

Ras activity levels control the development of pancreatic diseases.

Huamin Wang, B. Ji, C. Logsdon, 2009, Gastroenterology.

Mast Cells in Tumor Microenvironment Promotes the In Vivo Growth of Pancreatic Ductal Adenocarcinoma

P. Hwu, Huamin Wang, J. Abbruzzese, 2011, Clinical Cancer Research.

SIAH and EGFR, Two RAS Pathway Biomarkers, are Highly Prognostic in Locally Advanced and Metastatic Breast Cancer

J. Winston, R. Qin, R. Perry, 2016, EBioMedicine.

Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy

S. Kopetz, Ying Ma, Vikas Kumar, 2009, Journal of hematology & oncology.

Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis.

X. Le, Qiang Li, K. Xie, 2011, Cancer research.

A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients

D. Richel, T. Ciuleanu, S. Cascinu, 2017, BMC Cancer.

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer

A. Dalgleish, D. Adamson, J. Stebbing, 2016, British Journal of Cancer.

Multimodality Treatment of Pancreatic Cancer With Liver Metastases Using Chemotherapy, Radiation Therapy, and/or Chinese Herbal Medicine

Zhongxing Liao, Zhiqiang Meng, Peng Wang, 2011, Pancreas.

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.

K. Hess, A. Rashid, F. Meric-Bernstam, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.

L. Ellis, S. Curley, E. Abdalla, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multiple Myeloma, Painful Neuropathy, Acupuncture?

Michael L. Wang, A. Forman, Q. Yi, 2009, American journal of clinical oncology.

Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models.

P. Hwu, G. Lizée, J. Abbruzzese, 2007, Vaccine.

Journal of Translational Medicine Clinical Significance of Braf Mutations in Metastatic Melanoma Metastatic Melanomabraf Mutationclinical Significance

D. Polsky, P. Chapman, I. Osman, 2022 .

A randomized phase II study of gemcitabine (G) plus the cardiac glycoside huachansu (H) in the treatment of patients with locally advanced (LAPC) or metastatic pancreatic cancer (MPC).

C. Garrett, L. Cohen, D. Chang, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals.

P. Hwu, J. Abbruzzese, P. Cano, 2011, Vaccine.

Significant effect of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survival.

Manal M. Hassan, Douglas B. Evans, R. Wolff, 2006, Cancer research.

Glutathione S‐transferase gene polymorphisms and risk and survival of pancreatic cancer

Manal M. Hassan, Douglas B. Evans, M. Hassan, 2007, Cancer.

Unusual Abdominal Tumors

D. Filippa, C. Portlock, D. Chang, 2016 .

Synthetic microRNA targeting glioma-associated antigen-1 protein.

Takahiro Mine, N. Tsuda, C. Ioannides, 2009, Methods in molecular biology.

Synthetic MicroRNA Designed to Target Glioma-Associated Antigen 1 Transcription Factor Inhibits Division and Induces Late Apoptosis in Pancreatic Tumor Cells

J. Abbruzzese, N. Tsuda, C. Ioannides, 2006, Clinical Cancer Research.

Downregulation of Human Endogenous Retrovirus Type K (HERV-K) Viral env RNA in Pancreatic Cancer Cells Decreases Cell Proliferation and Tumor Growth

Donghui Li, Yue Lu, Jianjun Shen, 2017, Clinical Cancer Research.

Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression

P. Hwu, Huamin Wang, J. Abbruzzese, 2012, Journal of Hematology & Oncology.

Second-line chemotherapy use in metastatic colon cancer varies by disease responsiveness.

S. Kopetz, R. Wolff, M. Overman, 2008, Clinical colorectal cancer.

A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients

D. Richel, D. V. Von Hoff, T. Ciuleanu, 2017, BMC Cancer.

Mast cells in pancreatic ductal adenocarcinoma

D. Chang, 2012, Oncoimmunology.

Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway.

I. Shureiqi, S. Kopetz, R. Wolff, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival rates among patients vaccinated following resection of colorectal cancer metastases in a phase II randomized study compared with contemporary controls.

J. Marshall, T. Crocenzi, D. Niedzwiecki, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Unusual abdominal tumors, case 2. Localized amyloid associated with gastric adenocarcinoma.

D. Filippa, C. Portlock, D. Chang, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A dendritic cell-based vaccine effects on T-cell responses compared with a viral vector vaccine when administered to patients following resection of colorectal metastases in a randomized phase II study.

J. Marshall, T. Crocenzi, D. Niedzwiecki, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer

A. Dalgleish, D. Adamson, J. Stebbing, 2016, British Journal of Cancer.

A randomized phase II study of gemcitabine (G) plus the cardiac glycoside huachansu (H) in the treatment of patients with locally advanced (LAPC) or metastatic pancreatic cancer (MPC).

C. Garrett, L. Cohen, D. Chang, 2011, Journal of Clinical Oncology.

Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer

S. Kopetz, R. Wolff, J. Abbruzzese, 2007 .

SyntheticMicroRNADesignedtoTargetGlioma-AssociatedAntigen1 TranscriptionFactor InhibitsDivisionand InducesLate Apoptosis inPancreaticTumorCells

J. Abbruzzese, C. Ioannides, D. Chang, 2006 .

Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis.

X. Le, Qiang Li, K. Xie, 2011, Cancer research.